ELZONRIS
Commercial- Indications
- BPDCN, CMML, Myelofibrosis, AML
Company intelligence / Profile preview
Odyssey Thera (formerly Odyssey Pharmaceuticals) developed a proprietary cell-based systems biology technology to identify new medicines for cancer and other diseases. The company's approach was validated through partnerships with major pharmaceutical firms and government agencies but there are no public reports of clinical-stage assets or approved drugs.[5]
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Odyssey Thera, Inc..